Pearl Cohen is an international law firm with offices in Israel, the United States, and the United Kingdom. Our strength is derived from decades of legal experience and an intimate knowledge of the cutting edge technological, legal, and transactional issues facing our clients in local and cross border matters. This combination of experience and knowledge allows us to provide sound and innovative advice to clients worldwide.
Orgenesis, a pioneering, global biotech company committed to lowering costs, accelerating commercialization, and transforming the delivery of cell and gene therapies (CGTs)...
United StatesFood, Drugs, Healthcare, Life Sciences
Orgenesis, a pioneering, global biotech company committed to
lowering costs, accelerating commercialization, and transforming
the delivery of cell and gene therapies (CGTs), announced it has
entered into an agreement to acquire the assets of Tamir
Biotechnology, Inc. ("TamirBio"), including ranpirnase,
TamirBio's broad spectrum anti-viral platform.
Mark Cohen, Senior Partner and the Chair of the
Life Science Practice Group, represents Orgenesis in its
commercial, corporate and intellectual property matters.
To view the slides from this program, please click here.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
